Hydrogel Toxin-Absorbing or Binding Nanoparticles

Patent metadata

Field	Value
Publication number	US-2017079909-A1
Application number	US-201515126342-A
Country	US
Kind code	A1
Filing date	Mar 20, 2015
Priority date	Mar 20, 2014
Publication date	Mar 23, 2017
Grant date	—

Abstract

The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

First claim

1 . A composition comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle, wherein said nanoparticle comprises a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular membrane configured for absorbing or binding said toxin.

2 . The composition of claim 1 , wherein the polymeric hydrogel comprises a material selected from the group consisting of poly(ethylene glycol) dimethacrylate (PEGDMA), silicone, gelatin, chitosan, alginate, polyester, poly(vinyl alcohol) and polyacrylamide, polyethylene oxide, polyvinyl alcohol, Carbopol®, polyacrylamidomethylpropanesulfonate, polyacrylic acid, a salt of acrylic acid (including sodium and sulfopropyl acrylate, 2-hydroxyethyl methacrylate), agarose, methylcellulose, hyaluronan, and copolymers thereof.

3 . (canceled)

4 . The composition of claim 1 , wherein, during use, the polymeric hydrogel comprises at least about 1% water (w/w).

5 . The composition of claim 1 , wherein the polymeric hydrogel possess a degree of flexibility suitable to be applied to a tissue or an organ.

6 . (canceled)

7 . The composition of claim 1 , wherein the inner core of the nanoparticle comprises a polymeric particle core, a silica particle core, or a metal, e.g., gold, particle core.

8 - 10 . (canceled)

11 . The composition of claim 1 , wherein the inner core of the nanoparticle comprises a biocompatible or a synthetic material selected from the group consisting of poly(lactic-c-glycolic acid) (PLGA), polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polylysine, and polyglutamic acid.

12 . The composition of claim 1 , wherein the inner core of the nanoparticle supports the outer surface of the nanoparticle.

13 . (canceled)

14 . The composition of claim 1 , wherein the cellular membrane of the nanoparticle comprises a plasma membrane or an intracellular membrane.

15 . (canceled)

16 . The composition of claim 1 , wherein the nanoparticle has a diameter from about 10 nm to about 10 um.

17 . The composition of claim 1 , wherein the nanoparticle substantially lacks constituents of the cell from which the cellular membrane is derived.

18 . (canceled)

19 . The composition of claim 1 , wherein the nanoparticle substantially maintains natural structural integrity or activity of the cellular membrane or the constituents of the cellular membrane.

20 . The composition of claim 1 , wherein the nanoparticle is biocompatible or biodegradable.

21 . The composition of claim 1 , wherein the inner core of the nanoparticle comprises PLGA and the outer surface of the nanoparticle comprises a plasma membrane derived from a red blood cell.

22 - 23 . (canceled)

24 . The composition of claim 1 , wherein the cellular membrane of the outer surface of the nanoparticle is configured to absorb or bind to a biological toxin.

25 - 32 . (canceled)

33 . The composition of claim 1 , wherein the polymeric hydrogel comprises hydrated polymeric networks that are either physically or covalently crosslinked with each other and/or with the nanoparticle(s).

34 . The composition of claim 1 , which further comprises a therapeutic agent, a prophylactic agent, a diagnostic or marker agent, a prognostic agent, an isolation agent, a monitoring agent, or a combination thereof.

35 - 48 . (canceled)

49 . The composition of claim 1 , which is configured to be a part of scaffolds in tissue engineering.

50 . (canceled)

51 . The composition of any of claim 1 , which is a toxin-neutralizing antimicrobial hydrogel.

52 - 54 . (canceled)

55 . A method for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject, which method comprises administering, to a subject in need, or to cells of said subject, an effective amount of a composition of claim 1 .

56 - 74 . (canceled)

75 . A method of preserving therapeutic functionality of a toxin-absorbing or binding nanoparticle, which method comprises impregnating a toxin-absorbing or binding nanoparticle in a polymeric hydrogel to form a composition comprising said polymeric hydrogel impregnated with said toxin-absorbing or binding nanoparticle, wherein said nanoparticle comprises a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular membrane configured for absorbing or binding said toxin.

76 - 80 . (canceled)

Assignees

• Univ California

Inventors

• Zhang Liangfang
• Hu Che-Ming Jack
• Gao Weiwei
• Copp Jonathan

Classifications

• A61K9/5153

  Polyesters, e.g. poly(lactide-co-glycolide) · CPC title

• A61L2300/404

  Biocides, antimicrobial agents, antiseptic agents · CPC title

• A61L27/52

  Hydrogels or hydrocolloids · CPC title

• A61L27/54

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• A61K35/58

  Reptiles (antigens from snakes A61K39/38) · CPC title